Several other equities research analysts also recently issued reports on the company. Zacks Investment Research raised Teladoc Health from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. Guggenheim began coverage on Teladoc Health in a research note on Wednesday, April 17th. They issued a “buy” rating for the company. Bank of America began coverage on Teladoc Health in a research note on Thursday. They issued a “buy” rating and a $65.00 price objective for the company. Stephens began coverage on Teladoc Health in a research note on Tuesday, April 16th. They issued an “overweight” rating and a $75.00 price objective for the company. Finally, TheStreet raised Teladoc Health from a “d+” rating to a “c” rating in a research note on Wednesday, February 20th. Three investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $82.68.
Shares of NYSE:TDOC traded down $0.59 during midday trading on Friday, reaching $58.67. The company had a trading volume of 711,564 shares, compared to its average volume of 1,441,698. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.42. Teladoc Health has a 1-year low of $42.08 and a 1-year high of $89.05. The firm has a market capitalization of $4.24 billion, a price-to-earnings ratio of -40.74 and a beta of 1.26.
In related news, President Peter A. Mcclennen sold 13,063 shares of the firm’s stock in a transaction that occurred on Friday, April 5th. The stock was sold at an average price of $57.14, for a total value of $746,419.82. Following the transaction, the president now directly owns 22,733 shares of the company’s stock, valued at approximately $1,298,963.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Andrew Turitz sold 31,960 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The shares were sold at an average price of $55.82, for a total value of $1,784,007.20. Following the completion of the transaction, the senior vice president now directly owns 13,455 shares in the company, valued at $751,058.10. The disclosure for this sale can be found here. Insiders have sold a total of 156,351 shares of company stock valued at $9,088,666 over the last ninety days. Company insiders own 3.95% of the company’s stock.
Hedge funds have recently modified their holdings of the stock. Enlightenment Research LLC acquired a new stake in Teladoc Health in the 4th quarter valued at approximately $25,000. Nikko Asset Management Americas Inc. acquired a new stake in Teladoc Health in the 4th quarter valued at approximately $25,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Teladoc Health in the 1st quarter valued at approximately $30,000. Tompkins Financial Corp acquired a new stake in Teladoc Health in the 1st quarter valued at approximately $31,000. Finally, Ffcm LLC acquired a new stake in Teladoc Health in the 4th quarter valued at approximately $32,000.
About Teladoc Health
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Read More: Trading Penny Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.